Stock SCYX SCYNEXIS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News SCYNEXIS, Inc.

Equities

SCYX

US8112922005

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
2.77 USD +14.94% Intraday chart for SCYNEXIS, Inc. +47.34% +24.22%
May. 08 Earnings Flash (SCYX) SCYNEXIS Reports Q1 Revenue $1.4M MT
May. 08 SCYNEXIS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Earnings Flash (SCYX) SCYNEXIS Reports Q1 Revenue $1.4M
MT
Scynexis: Q1 Earnings Snapshot
AQ
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
AQ
SCYNEXIS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
AQ
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
AQ
SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases
CI
SCYNEXIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
AQ
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
AQ
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
AQ
SCYNEXIS, Inc. Presents Preclinical Data on Second Generation Fungerp SCY-247 Against Mucormycosis At the 11Th Advances Against Aspergillosis and Mucormycosis Conference
CI
Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
PR
SCYX DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important January 8 Deadline in Securities Class Action - SCYX
NE
SCYX Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX
PR
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
AQ
SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
PR
SCYNEXIS Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options
PR
SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SCYX Stock
  4. News SCYNEXIS, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW